NO20062930L - Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779 - Google Patents

Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779

Info

Publication number
NO20062930L
NO20062930L NO20062930A NO20062930A NO20062930L NO 20062930 L NO20062930 L NO 20062930L NO 20062930 A NO20062930 A NO 20062930A NO 20062930 A NO20062930 A NO 20062930A NO 20062930 L NO20062930 L NO 20062930L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
directly compressible
oral administration
compressible pharmaceutical
directly
Prior art date
Application number
NO20062930A
Other languages
English (en)
Norwegian (no)
Inventor
Muhammad Ashraf
Eric J Benjamin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20062930L publication Critical patent/NO20062930L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20062930A 2004-01-08 2006-06-22 Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779 NO20062930L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53495104P 2004-01-08 2004-01-08
PCT/US2004/042178 WO2005070393A2 (en) 2004-01-08 2004-12-14 Directly compressible pharmaceutical composition of the rapamycin ester cci-779

Publications (1)

Publication Number Publication Date
NO20062930L true NO20062930L (no) 2006-10-02

Family

ID=34806893

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062930A NO20062930L (no) 2004-01-08 2006-06-22 Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779

Country Status (30)

Country Link
US (1) US20050152983A1 (pl)
EP (1) EP1701698B1 (pl)
JP (1) JP2007517879A (pl)
KR (1) KR20060130162A (pl)
CN (1) CN1921861A (pl)
AR (1) AR047180A1 (pl)
AT (1) ATE383859T1 (pl)
AU (1) AU2004314213A1 (pl)
BR (1) BRPI0418373A (pl)
CA (1) CA2552595A1 (pl)
CR (1) CR8491A (pl)
CY (1) CY1107373T1 (pl)
DE (1) DE602004011398T2 (pl)
DK (1) DK1701698T3 (pl)
EC (1) ECSP066757A (pl)
ES (1) ES2298861T3 (pl)
GT (1) GT200500003A (pl)
HN (1) HN2005000005A (pl)
IL (1) IL176519A0 (pl)
MX (1) MXPA06007829A (pl)
NO (1) NO20062930L (pl)
PA (1) PA8621201A1 (pl)
PE (1) PE20050683A1 (pl)
PL (1) PL1701698T3 (pl)
PT (1) PT1701698E (pl)
RU (1) RU2006122517A (pl)
TW (1) TW200526213A (pl)
UA (1) UA84903C2 (pl)
WO (1) WO2005070393A2 (pl)
ZA (1) ZA200605631B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005023254A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
CA2562952A1 (en) * 2004-04-14 2005-11-10 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
BRPI0510277A (pt) * 2004-04-27 2007-10-30 Wyeth Corp método para marcar especificamente uma rapamicina, rapamicina especificamente marcada, composição, e, kit
KR20070104908A (ko) * 2005-02-15 2007-10-29 와이어쓰 경구적으로 생체이용가능한 ｃｃｉ-779 정제 제형물
AU2006315512B2 (en) 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
US9364502B2 (en) * 2006-06-28 2016-06-14 Emisphere Technologies, Inc. Gallium nitrate formulations
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
JP2013527223A (ja) 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104721158B (zh) * 2013-12-24 2018-01-30 正大天晴药业集团股份有限公司 一种稳定的依维莫司片剂
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US20190022073A1 (en) * 2015-09-03 2019-01-24 Nippon Kayaku Kabushiki Kaisha Pharmaceutical composition comprising rapamycin or derivative thereof
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5928668A (en) * 1993-12-21 1999-07-27 Applied Analytical Industries, Inc. Method for dry blend compression of medicaments
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
BR0314397A (pt) * 2002-09-17 2005-08-09 Wyeth Corp Formulações orais
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
JP2007500191A (ja) * 2003-07-25 2007-01-11 ワイス Ｃｃｉ−７７９の凍結乾燥処方
RU2339639C2 (ru) * 2003-08-07 2008-11-27 Уайт Региоселективный синтез cci-779
WO2005023254A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
US20060142422A1 (en) * 2004-12-07 2006-06-29 Toshikazu Kobayashi Hydrolysis resistant polyester compositions and articles made therefrom
KR20070104908A (ko) * 2005-02-15 2007-10-29 와이어쓰 경구적으로 생체이용가능한 ｃｃｉ-779 정제 제형물

Also Published As

Publication number Publication date
DK1701698T3 (da) 2008-05-05
ATE383859T1 (de) 2008-02-15
EP1701698B1 (en) 2008-01-16
PT1701698E (pt) 2008-03-27
DE602004011398D1 (de) 2008-03-06
BRPI0418373A (pt) 2007-05-22
TW200526213A (en) 2005-08-16
CN1921861A (zh) 2007-02-28
CR8491A (es) 2008-08-21
AR047180A1 (es) 2006-01-11
WO2005070393A2 (en) 2005-08-04
ECSP066757A (es) 2006-11-16
IL176519A0 (en) 2006-10-05
WO2005070393A3 (en) 2006-09-28
HK1090308A1 (en) 2006-12-22
ZA200605631B (en) 2010-01-27
DE602004011398T2 (de) 2009-01-15
EP1701698A2 (en) 2006-09-20
GT200500003A (es) 2005-08-18
RU2006122517A (ru) 2008-02-20
CA2552595A1 (en) 2005-08-04
ES2298861T3 (es) 2008-05-16
UA84903C2 (ru) 2008-12-10
US20050152983A1 (en) 2005-07-14
JP2007517879A (ja) 2007-07-05
CY1107373T1 (el) 2012-12-19
PE20050683A1 (es) 2005-11-04
HN2005000005A (es) 2009-04-17
PL1701698T3 (pl) 2008-03-31
MXPA06007829A (es) 2006-09-01
PA8621201A1 (es) 2005-12-23
AU2004314213A1 (en) 2005-08-04
KR20060130162A (ko) 2006-12-18

Similar Documents

Publication Publication Date Title
NO20062930L (no) Direkte komprimerbar farmasoytisk sammensetning for oral administrering av CC-779
ES2729679T3 (es) Derivados de morfinano para el tratamiento de la sobredosis de fármacos
NO20073786L (no) Oralt biotilgjengelige CCI-779-formuleringer
DE60003837D1 (de) Tetrapeptid, das die funktionelle aktivität von neuronen stimuliert, dieses enthaltendes pharmakologisches mittel und seine verwendung
DK1725233T3 (da) Farmaceutisk sammensætning omfattende SNS-595 og anvendelse deraf
AR063782A1 (es) Parche y metodo transdermico para emesis
MX2009010268A (es) Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina.
Hung et al. Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
EP2392322A3 (en) Dosing regimes for trans-clomiphene
IL194500A (en) A peptide substance capable of increasing capillary resistance and pharmacological preparation containing the above
NO20065152L (no) Formulering med vedvarende frigivelse for oral administrering av HMG-COA-reduktaseinhibitor, og fremgansmate for fremstilling derav
ATE283036T1 (de) Pharmazeutische zusammensetzung mit gesteuerter freigabe enthaltend midodrin und/oder desglymidodrin
GEP201606538B (en) Preoperative treatment of post operative pain
RU2005131578A (ru) Аплидин для лечения множественной миеломы
ATE513845T1 (de) Peptidsubstanz mit immunogeroprotektiver wirkung, darauf basierende pharmazeutische zusammensetzung und verfahren zu ihrer anwendung
DE602005021115D1 (de) Verfahren und zusammensetzungen zur oralen fts-abgabe
CA2425445A1 (en) Tetrapeptide stimulating functional activity of hepatocytes, pharmacological substance on its basis and the method of its application
RU2008137533A (ru) Органические соединения
Malacco et al. Comparison of valsartan and irbesartan in the treatment of mild to moderate hypertension: a randomized, open-label, crossover study
BR0307452A (pt) Composição oral de trimetobenzamida para tratar e controlar náusea e/ou vÈmito
RU2003134216A (ru) Способ лечения остеохондроза позвоночника короткими интенсивными курсами
RU2531941C1 (ru) Способ профилактики и лечения инфекционных процессов при хирургических стоматологических вмешательствах
UA143037U (uk) Спосіб профілактики та лікування фантомного больового синдрому у пацієнтів після ампутації нижньої кінцівки
SASAKI et al. Effusion level of exodontia wound after oral administration of cefdinir (CFDN)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application